CATHERINE DOTY: Open Payments
NPI 1316015696 · NEWPORT, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,615 in 64 payments from 14 companies in 2025. Trend: 2023 $2,636 · 2024 $1,488 · 2025 $1,615
Food & beverage: $1,615
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $509 |
| Axsome Therapeutics, Inc. | 9 | $135 |
| Neurocrine BioSciences, Inc. | 5 | $132 |
| Alkermes, Inc. | 5 | $132 |
| Lundbeck LLC | 4 | $108 |
| Otsuka America Pharmaceutical, Inc. | 5 | $108 |
| E.R. Squibb & Sons, L.L.C. | 4 | $100 |
| Janssen Pharmaceuticals, Inc | 4 | $86 |
| Vanda Pharmaceuticals Inc. | 4 | $85 |
| Tris Pharma Inc | 4 | $68 |
Products named: CAPLYTA, REXULTI, INGREZZA, LYBALVI, Auvelity, COBENFY, Dyanavel XR, HETLIOZ.
Industry payments across DE — which companies pay providers there.
